Poor
Needs Revision
Patient Risk:
Moderate
Summary
Only the basic FDA-approved indications were clearly supported by the provided label excerpts. Most other claims (specific infection/CV/cancer/post-marketing/patent statements and adverse-event specifics) were not supported by provided label text and were therefore not auditable against the label excerpts. Several safety-related recommendations/generalizations also were not clearly anchored to the label wording.
Category Scores
Accurate Statements
Dupixent (dupilumab) is a medication used to treat asthma.
Supported by provided label excerpt: 1.2 Asthma
Dupixent (dupilumab) is a medication used to treat eczema (atopic dermatitis).
Supported by provided label excerpt: 1.1 Atopic Dermatitis
Dupixent (dupilumab) is a medication used to treat chronic rhinosinusitis with nasal polyps.
Supported by provided label excerpt: 1.3 Chronic Rhinosinusitis with Nasal Polyps
The US FDA has approved Dupixent for multiple indications.
Supported by provided label excerpt: 1 INDICATIONS AND USAGE (1.1, 1.2, 1.3)
The European Medicines Agency has also approved Dupixent for various indications.
Not supported by provided FDA label excerpts (EMA approvals are not in provided label); claim treated as unsupported/inauditable.
Unsupported Statements
A study found that patients taking Dupixent for up to 2 years had a higher risk of infections, including nasopharyngitis and respiratory tract infections.
No supporting FDA label excerpt was provided for this specific 2-year infection-risk finding or these specific infection terms.
Infections reported in patients taking Dupixent for up to 2 years were generally mild and resolved on their own.
No supporting FDA label excerpt was provided for this characterization.
A 2020 US FDA Oncology Drug Advisory Committee review concluded there was no conclusive evidence that Dupixent increases the risk of cancer.
No such advisory committee conclusion appears in the provided label excerpts.
The US FDA mandated post-marketing studies to continue monitoring Dupixent's long-term safety.
The provided label excerpt (6.2 Postmarketing Experience) describes post-approval use and reporting limitations, but no mandated-studies statement was provided.
A study found that patients taking Dupixent for up to 6 months had a higher risk of cardiovascular events, such as myocardial infarction and stroke, compared to those not taking the medication.
No supporting FDA label excerpt was provided for this specific 6-month cardiovascular-risk finding.
The study assessing cardiovascular risk was limited.
No label excerpt was provided addressing study limitations for cardiovascular risk.
Patients taking Dupixent may experience injection site reactions.
No injection-site-reaction adverse reaction was provided in the supplied label excerpts.
Patients taking Dupixent may experience nasopharyngitis.
No nasopharyngitis adverse reaction wording was provided in the supplied label excerpts.
Patients taking Dupixent may experience upper respiratory tract infections.
No URTI adverse reaction wording was provided in the supplied label excerpts.
Dupixent may cause increased eosinophils.
The provided excerpt (5.3) discusses eosinophilia in the clinical context of asthma patients and eosinophilic conditions, but the claim is not explicitly supported as a stated adverse effect ('increased eosinophils').
Increased eosinophils from Dupixent may lead to asthma exacerbations.
No label excerpt provided this causal linkage.
It is generally recommended that patients discontinue Dupixent treatment under the guidance of their healthcare provider.
The provided label excerpts discuss specific 'withhold' consideration for suspected eosinophilic pneumonia/EGPA and discontinuation for certain helminth situations; generalized 'generally recommended discontinue' is not directly supported.
Stopping Dupixent abruptly can lead to rebound effects.
No rebound-effects statement was provided in the supplied label excerpts.
Stopping Dupixent abruptly can lead to asthma exacerbations.
The supplied label excerpt warns against abrupt discontinuation of corticosteroids, but does not provide label text supporting abrupt DUPIXENT discontinuation leading to asthma exacerbations.
Stopping Dupixent abruptly can lead to atopic dermatitis flares.
No label excerpt provided support for abrupt DUPIXENT discontinuation leading to atopic dermatitis flares.
The European Medicines Agency has also approved Dupixent for various indications.
No EMA approval information was provided in the supplied FDA label excerpts.
As of 2023, Dupixent is patent-protected.
Patent status is not provided in the supplied FDA label excerpts.
The patent for Dupixent is stated to expire in the US in 2034.
Patent expiry timing is not provided in the supplied FDA label excerpts.
The patent for Dupixent is expected to expire in Europe in 2036.
Patent expiry timing is not provided in the supplied FDA label excerpts.
Contradictions
Important Omissions
Boxed warning status and specific boxed warnings (if any) were not evaluated, despite multiple safety-related claims being made.
Importance:
Moderate
No FDA-label-supported dose/discontinuation/missed-dose safety context was included in the extracted claims, even though the user asked (via extracted claims) about long-term safety and abrupt stopping implications.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several extracted safety claims (specific infection types/durations, cardiovascular events, injection-site reactions, nasopharyngitis/URTI, and eosinophil/inflammatory consequences) and generalized discontinuation/rebound assertions were not supported by the provided FDA label excerpts. Unsupported safety guidance could mislead clinical interpretation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Most extracted claims lack support from the provided FDA prescribing-information excerpts (many were treated as 'absent from label' or not verifiable) and several safety/general discontinuation statements are not anchored to label wording provided (notably eosinophils and abrupt DUPIXENT stopping claims).
Suggested Improvement
Restrict extracted claims to text explicitly present in the provided label sections (e.g., specific indications 1.1/1.2/1.3; eosinophilic condition management 'consider withholding' in 5.3; corticosteroid reduction warning in 5.5; helminth infection discontinuation in 5.9). Remove or rephrase unsupported study/patent/EMA/committee and generalized discontinuation/rebound assertions unless corresponding FDA label text is provided.